Regeneron Acquires 23andMe for $256 Million in Bankruptcy Auction
Biotech giant Regeneron Pharmaceuticals has announced plans to acquire genetic testing firm 23andMe for $256 million, following the company’s bankruptcy proceedings. The deal was confirmed on Monday and is expected to be finalized in the third quarter of 2025. The acquisition comes after 23andMe filed for bankruptcy in March amid falling demand for its ancestry…